In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting
Background Neurofilament light chain (NFL) is a neuroaxonal cytoskeletal protein released into cerebrospinal fluid (CSF) and eventually into blood upon neuronal injury. Its detection in serum (sNFL) makes it a promising marker in multiple sclerosis (MS). Objective To evaluate the usefulness of a sin...
Gespeichert in:
| Veröffentlicht in: | Journal of neurology 2024-12, Vol.271 (12), p.7494-7501 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7501 |
|---|---|
| container_issue | 12 |
| container_start_page | 7494 |
| container_title | Journal of neurology |
| container_volume | 271 |
| creator | Malucchi, Simona Bava, Cecilia Irene Valentino, Paola Martire, Serena Lo Re, Marianna Bertolotto, Antonio Di Sapio, Alessia |
| description | Background
Neurofilament light chain (NFL) is a neuroaxonal cytoskeletal protein released into cerebrospinal fluid (CSF) and eventually into blood upon neuronal injury. Its detection in serum (sNFL) makes it a promising marker in multiple sclerosis (MS).
Objective
To evaluate the usefulness of a single dosage of sNFL in clinical practice.
Methods
626 consecutive relapsing–remitting (RR) MS patients treated with disease modifying treatments (DMTs) for at least 12 months underwent a single sNFL dosage. 553 patients had NEDA-3 status (no relapses, no disability progression, no new/enlarging or contrast-enhancing lesions on brain magnetic resonance imaging) in the 12 months prior blood sampling. sNFL levels were measured by single molecule array (Simoa™)
.
Association between sNFL levels and NEDA-3 status at 12, 24, and 36 months was evaluated with logistic regression models adjusted for sex, EDSS, disease duration, and type of DMTs.
Results
469 out of the 553 NEDA-3 patients had normal sNFL level, whereas 42 had elevated level. The two groups did not differ regarding baseline characteristics. A very strong association between elevated sNFL levels and loss of NEDA-3 status within 12 months was found, with an odds ratio [OR] of 10.74 (95% CI 4.34–26.57); 15 and 10 patients with normal and elevated sNFL, respectively lost NEDA-3 (
p
|
| doi_str_mv | 10.1007/s00415-024-12701-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3108763367</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3108763367</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-4490ee9d7da436c840975a2eb4a57db3b8c4a7ba34545e59ce1db1083011b1893</originalsourceid><addsrcrecordid>eNp9kU1uFDEUhC0EIkPgAiyQJTZh0WC37f5hF0UEIo1gA-vWa_ebGUdue_Bza5TbcABOwcnwMAEkFqy8qK-qnlyMPZfitRSifUNCaGkqUetK1q2Q1eEBW0mt6kpq0z9kK6G0qIwy-ow9IboVQnRFeMzOVK-kalS3Yt9vAp8Xn93eIyfrMUVyxPeQHYZMHDi5sD1qmJaZB1xS3DgPc1G5d9td5nYHLvAL-ni9fsWnSLBFXiIop1icdxyIonWQceIHl3dc1j--zTHkHfG4ZBtnfMsnyMA3Kc6lMCH4yrsNcutdcBZ8Kc-5nPGUPdqAJ3x2_56zL9fvPl99qNaf3t9cXa4rW5smV1r3ArGf2gm0amynRd8aqHHUYNppVGNnNbQjKG20QdNblNMoRaeElKPsenXOLk65-xS_Lkh5mB1Z9B4CxoUGVeC2UappC_ryH_Q2LimU6wql6qZvGn2k6hNly_dSws2wT26GdDdIMRy3HE5bDmXL4deWw6GYXtxHL-OM0x_L7_EKoE4AFSlsMf3t_k_sT3GIrSM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3132696647</pqid></control><display><type>article</type><title>In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Malucchi, Simona ; Bava, Cecilia Irene ; Valentino, Paola ; Martire, Serena ; Lo Re, Marianna ; Bertolotto, Antonio ; Di Sapio, Alessia</creator><creatorcontrib>Malucchi, Simona ; Bava, Cecilia Irene ; Valentino, Paola ; Martire, Serena ; Lo Re, Marianna ; Bertolotto, Antonio ; Di Sapio, Alessia</creatorcontrib><description>Background
Neurofilament light chain (NFL) is a neuroaxonal cytoskeletal protein released into cerebrospinal fluid (CSF) and eventually into blood upon neuronal injury. Its detection in serum (sNFL) makes it a promising marker in multiple sclerosis (MS).
Objective
To evaluate the usefulness of a single dosage of sNFL in clinical practice.
Methods
626 consecutive relapsing–remitting (RR) MS patients treated with disease modifying treatments (DMTs) for at least 12 months underwent a single sNFL dosage. 553 patients had NEDA-3 status (no relapses, no disability progression, no new/enlarging or contrast-enhancing lesions on brain magnetic resonance imaging) in the 12 months prior blood sampling. sNFL levels were measured by single molecule array (Simoa™)
.
Association between sNFL levels and NEDA-3 status at 12, 24, and 36 months was evaluated with logistic regression models adjusted for sex, EDSS, disease duration, and type of DMTs.
Results
469 out of the 553 NEDA-3 patients had normal sNFL level, whereas 42 had elevated level. The two groups did not differ regarding baseline characteristics. A very strong association between elevated sNFL levels and loss of NEDA-3 status within 12 months was found, with an odds ratio [OR] of 10.74 (95% CI 4.34–26.57); 15 and 10 patients with normal and elevated sNFL, respectively lost NEDA-3 (
p
< 0.001). The effect was not detected during the subsequent 13–24 and 25–36 months.
Conclusions
A single elevated sNFL is strongly associated with NEDA-3 loss within 1 year. Elevated sNFL in apparently stable patients suggests an ongoing disease activity below the detection threshold of standard parameters.</description><identifier>ISSN: 0340-5354</identifier><identifier>ISSN: 1432-1459</identifier><identifier>EISSN: 1432-1459</identifier><identifier>DOI: 10.1007/s00415-024-12701-w</identifier><identifier>PMID: 39313638</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Biomarkers - blood ; Blood levels ; Cerebrospinal fluid ; Cytoskeleton ; Disability Evaluation ; Disease Progression ; Dosage ; Female ; Follow-Up Studies ; Humans ; Magnetic Resonance Imaging ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis - blood ; Multiple Sclerosis - diagnostic imaging ; Multiple Sclerosis, Relapsing-Remitting - blood ; Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Neurofilament Proteins - blood ; Neurofilament Proteins - cerebrospinal fluid ; Neuroimaging ; Neurology ; Neuroradiology ; Neurosciences ; Original Communication ; Regression analysis</subject><ispartof>Journal of neurology, 2024-12, Vol.271 (12), p.7494-7501</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-4490ee9d7da436c840975a2eb4a57db3b8c4a7ba34545e59ce1db1083011b1893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00415-024-12701-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00415-024-12701-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39313638$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Malucchi, Simona</creatorcontrib><creatorcontrib>Bava, Cecilia Irene</creatorcontrib><creatorcontrib>Valentino, Paola</creatorcontrib><creatorcontrib>Martire, Serena</creatorcontrib><creatorcontrib>Lo Re, Marianna</creatorcontrib><creatorcontrib>Bertolotto, Antonio</creatorcontrib><creatorcontrib>Di Sapio, Alessia</creatorcontrib><title>In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting</title><title>Journal of neurology</title><addtitle>J Neurol</addtitle><addtitle>J Neurol</addtitle><description>Background
Neurofilament light chain (NFL) is a neuroaxonal cytoskeletal protein released into cerebrospinal fluid (CSF) and eventually into blood upon neuronal injury. Its detection in serum (sNFL) makes it a promising marker in multiple sclerosis (MS).
Objective
To evaluate the usefulness of a single dosage of sNFL in clinical practice.
Methods
626 consecutive relapsing–remitting (RR) MS patients treated with disease modifying treatments (DMTs) for at least 12 months underwent a single sNFL dosage. 553 patients had NEDA-3 status (no relapses, no disability progression, no new/enlarging or contrast-enhancing lesions on brain magnetic resonance imaging) in the 12 months prior blood sampling. sNFL levels were measured by single molecule array (Simoa™)
.
Association between sNFL levels and NEDA-3 status at 12, 24, and 36 months was evaluated with logistic regression models adjusted for sex, EDSS, disease duration, and type of DMTs.
Results
469 out of the 553 NEDA-3 patients had normal sNFL level, whereas 42 had elevated level. The two groups did not differ regarding baseline characteristics. A very strong association between elevated sNFL levels and loss of NEDA-3 status within 12 months was found, with an odds ratio [OR] of 10.74 (95% CI 4.34–26.57); 15 and 10 patients with normal and elevated sNFL, respectively lost NEDA-3 (
p
< 0.001). The effect was not detected during the subsequent 13–24 and 25–36 months.
Conclusions
A single elevated sNFL is strongly associated with NEDA-3 loss within 1 year. Elevated sNFL in apparently stable patients suggests an ongoing disease activity below the detection threshold of standard parameters.</description><subject>Adult</subject><subject>Biomarkers - blood</subject><subject>Blood levels</subject><subject>Cerebrospinal fluid</subject><subject>Cytoskeleton</subject><subject>Disability Evaluation</subject><subject>Disease Progression</subject><subject>Dosage</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - blood</subject><subject>Multiple Sclerosis - diagnostic imaging</subject><subject>Multiple Sclerosis, Relapsing-Remitting - blood</subject><subject>Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Neurofilament Proteins - blood</subject><subject>Neurofilament Proteins - cerebrospinal fluid</subject><subject>Neuroimaging</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosciences</subject><subject>Original Communication</subject><subject>Regression analysis</subject><issn>0340-5354</issn><issn>1432-1459</issn><issn>1432-1459</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1uFDEUhC0EIkPgAiyQJTZh0WC37f5hF0UEIo1gA-vWa_ebGUdue_Bza5TbcABOwcnwMAEkFqy8qK-qnlyMPZfitRSifUNCaGkqUetK1q2Q1eEBW0mt6kpq0z9kK6G0qIwy-ow9IboVQnRFeMzOVK-kalS3Yt9vAp8Xn93eIyfrMUVyxPeQHYZMHDi5sD1qmJaZB1xS3DgPc1G5d9td5nYHLvAL-ni9fsWnSLBFXiIop1icdxyIonWQceIHl3dc1j--zTHkHfG4ZBtnfMsnyMA3Kc6lMCH4yrsNcutdcBZ8Kc-5nPGUPdqAJ3x2_56zL9fvPl99qNaf3t9cXa4rW5smV1r3ArGf2gm0amynRd8aqHHUYNppVGNnNbQjKG20QdNblNMoRaeElKPsenXOLk65-xS_Lkh5mB1Z9B4CxoUGVeC2UappC_ryH_Q2LimU6wql6qZvGn2k6hNly_dSws2wT26GdDdIMRy3HE5bDmXL4deWw6GYXtxHL-OM0x_L7_EKoE4AFSlsMf3t_k_sT3GIrSM</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Malucchi, Simona</creator><creator>Bava, Cecilia Irene</creator><creator>Valentino, Paola</creator><creator>Martire, Serena</creator><creator>Lo Re, Marianna</creator><creator>Bertolotto, Antonio</creator><creator>Di Sapio, Alessia</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20241201</creationdate><title>In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting</title><author>Malucchi, Simona ; Bava, Cecilia Irene ; Valentino, Paola ; Martire, Serena ; Lo Re, Marianna ; Bertolotto, Antonio ; Di Sapio, Alessia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-4490ee9d7da436c840975a2eb4a57db3b8c4a7ba34545e59ce1db1083011b1893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Biomarkers - blood</topic><topic>Blood levels</topic><topic>Cerebrospinal fluid</topic><topic>Cytoskeleton</topic><topic>Disability Evaluation</topic><topic>Disease Progression</topic><topic>Dosage</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - blood</topic><topic>Multiple Sclerosis - diagnostic imaging</topic><topic>Multiple Sclerosis, Relapsing-Remitting - blood</topic><topic>Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Neurofilament Proteins - blood</topic><topic>Neurofilament Proteins - cerebrospinal fluid</topic><topic>Neuroimaging</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosciences</topic><topic>Original Communication</topic><topic>Regression analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Malucchi, Simona</creatorcontrib><creatorcontrib>Bava, Cecilia Irene</creatorcontrib><creatorcontrib>Valentino, Paola</creatorcontrib><creatorcontrib>Martire, Serena</creatorcontrib><creatorcontrib>Lo Re, Marianna</creatorcontrib><creatorcontrib>Bertolotto, Antonio</creatorcontrib><creatorcontrib>Di Sapio, Alessia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malucchi, Simona</au><au>Bava, Cecilia Irene</au><au>Valentino, Paola</au><au>Martire, Serena</au><au>Lo Re, Marianna</au><au>Bertolotto, Antonio</au><au>Di Sapio, Alessia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting</atitle><jtitle>Journal of neurology</jtitle><stitle>J Neurol</stitle><addtitle>J Neurol</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>271</volume><issue>12</issue><spage>7494</spage><epage>7501</epage><pages>7494-7501</pages><issn>0340-5354</issn><issn>1432-1459</issn><eissn>1432-1459</eissn><abstract>Background
Neurofilament light chain (NFL) is a neuroaxonal cytoskeletal protein released into cerebrospinal fluid (CSF) and eventually into blood upon neuronal injury. Its detection in serum (sNFL) makes it a promising marker in multiple sclerosis (MS).
Objective
To evaluate the usefulness of a single dosage of sNFL in clinical practice.
Methods
626 consecutive relapsing–remitting (RR) MS patients treated with disease modifying treatments (DMTs) for at least 12 months underwent a single sNFL dosage. 553 patients had NEDA-3 status (no relapses, no disability progression, no new/enlarging or contrast-enhancing lesions on brain magnetic resonance imaging) in the 12 months prior blood sampling. sNFL levels were measured by single molecule array (Simoa™)
.
Association between sNFL levels and NEDA-3 status at 12, 24, and 36 months was evaluated with logistic regression models adjusted for sex, EDSS, disease duration, and type of DMTs.
Results
469 out of the 553 NEDA-3 patients had normal sNFL level, whereas 42 had elevated level. The two groups did not differ regarding baseline characteristics. A very strong association between elevated sNFL levels and loss of NEDA-3 status within 12 months was found, with an odds ratio [OR] of 10.74 (95% CI 4.34–26.57); 15 and 10 patients with normal and elevated sNFL, respectively lost NEDA-3 (
p
< 0.001). The effect was not detected during the subsequent 13–24 and 25–36 months.
Conclusions
A single elevated sNFL is strongly associated with NEDA-3 loss within 1 year. Elevated sNFL in apparently stable patients suggests an ongoing disease activity below the detection threshold of standard parameters.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>39313638</pmid><doi>10.1007/s00415-024-12701-w</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-5354 |
| ispartof | Journal of neurology, 2024-12, Vol.271 (12), p.7494-7501 |
| issn | 0340-5354 1432-1459 1432-1459 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3108763367 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Biomarkers - blood Blood levels Cerebrospinal fluid Cytoskeleton Disability Evaluation Disease Progression Dosage Female Follow-Up Studies Humans Magnetic Resonance Imaging Male Medicine Medicine & Public Health Middle Aged Multiple sclerosis Multiple Sclerosis - blood Multiple Sclerosis - diagnostic imaging Multiple Sclerosis, Relapsing-Remitting - blood Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging Multiple Sclerosis, Relapsing-Remitting - drug therapy Neurofilament Proteins - blood Neurofilament Proteins - cerebrospinal fluid Neuroimaging Neurology Neuroradiology Neurosciences Original Communication Regression analysis |
| title | In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A13%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20multiple%20sclerosis%20patients%20a%20single%20serum%20neurofilament%20light%20chain%20(sNFL)%20dosage%20is%20strongly%20associated%20with%2012%C2%A0months%20outcome:%20data%20from%20a%20real-life%20clinical%20setting&rft.jtitle=Journal%20of%20neurology&rft.au=Malucchi,%20Simona&rft.date=2024-12-01&rft.volume=271&rft.issue=12&rft.spage=7494&rft.epage=7501&rft.pages=7494-7501&rft.issn=0340-5354&rft.eissn=1432-1459&rft_id=info:doi/10.1007/s00415-024-12701-w&rft_dat=%3Cproquest_cross%3E3108763367%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3132696647&rft_id=info:pmid/39313638&rfr_iscdi=true |